Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 8

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 8
---
, or combination of risk factors, may cause actual
results to differ materially from those contained in any forward-looking statements. These risks and others described under the section
“Risk Factors” in this prospectus supplement, the accompanying prospectus and any documents we incorporate by reference
are not exhaustive.

Given these uncertainties, you are cautioned
not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce
the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

| S-4 |

### SUMMARY
The following summary highlights selected information contained elsewhere in or incorporated by reference into this prospectus supplement and the accompanying prospectus. The summary may not contain all of the information that you should consider before investing in our common shares. You should read this entire prospectus supplement and the accompanying prospectus carefully, including “Risk Factors” contained in this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, before making an investment decision. This prospectus supplement may add to, update or change information in the accompanying prospectus. See the “Risk Factors” section of this prospectus supplement beginning on page S-7 for a discussion of the risks involved in investing in our securities.

#### Our Company
We are a biopharmaceutical company developing innovative
ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on
mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where
there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable
market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory.

In Medical Dermatology we are developing EB06, an anti-CXCL10
monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches.
CXCL10 has been shown to play a key role in the disease, and neutralization of CXCL10 has been demonstrated to both prevent and reverse
depigmentation in animal models. To date, EB06 has demonstrated a favorable safety and tolerability profile. We have received regulatory
approval from Health Canada to conduct a Phase 2 proof of concept study of EB06 in patients with moderate-to-severe nonsegmental vitil